iHuman Inc. provides children's entertainment products and services to individual users, educational organizations and distributors in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
| Revenue (TTM) | $744.09M |
| Gross Profit (TTM) | $496.68M |
| EBITDA | $-1.06M |
| Operating Margin | -12.00% |
| Return on Equity | 2.59% |
| Return on Assets | -0.28% |
| Revenue/Share (TTM) | $14.48 |
| Book Value | $2.43 |
| Price-to-Book | 0.42 |
| Price-to-Sales (TTM) | 0.08 |
| EV/Revenue | 0.0484 |
| EV/EBITDA | 0.75 |
| Quarterly Earnings Growth (YoY) | -82.30% |
| Quarterly Revenue Growth (YoY) | -13.40% |
| Shares Outstanding | $22.32M |
| Float | $14.07M |
| % Insiders | 0.04% |
| % Institutions | 0.59% |
Volatility is currently expanding
BEIJING, Sept. 29, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered knowledge and personal growth products, today announced its unaudited financial results for the second quarter ended June 30, 2026.
BEIJING, June 29, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered knowledge and personal growth products, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Revenues were RMB182.5 million (US$26.5 million), compared with RMB210.4 million in the same period last year.
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.
BEIJING, April 24, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 24, 2026. The annual report on Form 20-F is available on the Company's investor relations website at https://ir.ihuman.com/.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IH and any ticker you trade — then tracks every position and per-strategy win rate.
